J&J drug shows promise in high-risk prostate cancer

Adding Johnson & Johnson's advanced prostate cancer drug, Zytiga, to hormone therapy before surgery has been shown for the first time to eradicate tumors in some men with high-risk forms of the disease. ...

Disappointment for Men With Advanced Prostate Cancer As Life-Extending Drug[1]Refused by NICE

GUILDFORD, England, May 11, 2012 /PRNewswire/ --Warning of an emerging 'postcode lottery' for men with advanced prostate cancer as NICE upholds its decision not to approve JEVTANA [ ®▼ ](cabazitaxel) for ...

Nice approves prostate cancer drug

A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.

Prostate cancer drug Abiraterone set for approval in England and Wales but not Scotland

Abiraterone, marketed as Zytiga, should be given to patients in England and Wales, after a U-turn by the NHS rationing body. It has already been turned down in Scotland.

Prostate cancer drug that can extend patients' lives by three months should be available on the NHS, says health ...

Abirateron, marketed as Zytiga, can extend the lives of late-stage cancer sufferers by more than three months.